Issue 5, 2013

Synthesis, activity and metabolic stability of non-ribose containing inhibitors of histone methyltransferase DOT1L

Abstract

Histone methyltransferase DOT1L is a drug target for MLL leukemia. We report an efficient synthesis of a cyclopentane-containing compound that potently and selectively inhibits DOT1L (Ki = 1.1 nM) as well as H3K79 methylation (IC50 ∼ 200 nM). Importantly, this compound exhibits a high stability in plasma and liver microsomes, suggesting it is a better drug candidate.

Graphical abstract: Synthesis, activity and metabolic stability of non-ribose containing inhibitors of histone methyltransferase DOT1L

Supplementary files

Article information

Article type
Concise Article
Submitted
16 Jan 2013
Accepted
12 Mar 2013
First published
12 Mar 2013

Med. Chem. Commun., 2013,4, 822-826

Synthesis, activity and metabolic stability of non-ribose containing inhibitors of histone methyltransferase DOT1L

L. Deng, L. Zhang, Y. Yao, C. Wang, M. S. Redell, S. Dong and Y. Song, Med. Chem. Commun., 2013, 4, 822 DOI: 10.1039/C3MD00021D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements